158 related articles for article (PubMed ID: 36738874)
1. Proteomics strategies for urothelial bladder cancer diagnosis, prognosis and treatment: Trends for tumor biomarker sources.
Tabaei S; Haghshenas MR; Webster TJ; Ghaderi A
Anal Biochem; 2023 Apr; 666():115074. PubMed ID: 36738874
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder.
Heicappell R; Schostak M; Müller M; Miller K
Scand J Clin Lab Invest; 2000 Jul; 60(4):275-82. PubMed ID: 10943597
[TBL] [Abstract][Full Text] [Related]
3. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder.
Babjuk M; Kostírová M; Mudra K; Pecher S; Smolová H; Pecen L; Ibrahim Z; Dvorácek J; Jarolím L; Novák J; Zima T
Eur Urol; 2002 Jan; 41(1):34-9. PubMed ID: 11999463
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder.
Mian C; Lodde M; Haitel A; Egarter Vigl E; Marberger M; Pycha A
Urology; 2000 Aug; 56(2):228-31. PubMed ID: 10925083
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive diagnostic potential of microRNA-203 in liquid biopsy of urothelial carcinoma of bladder.
Singh P; Singh A; Gupta N; Raja KD; Singh P; Agarwal S; Sharma A
Mol Cell Biochem; 2022 Sep; 477(9):2173-2182. PubMed ID: 35445913
[TBL] [Abstract][Full Text] [Related]
8. Malignancy Grade-Dependent Mapping of Metabolic Landscapes in Human Urothelial Bladder Cancer: Identification of Novel, Diagnostic, and Druggable Biomarkers.
Iliou A; Panagiotakis A; Giannopoulou AF; Benaki D; Kosmopoulou M; Velentzas AD; Tsitsilonis OE; Papassideri IS; Voutsinas GE; Konstantakou EG; Gikas E; Mikros E; Stravopodis DJ
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32164285
[TBL] [Abstract][Full Text] [Related]
9. Proteomic Profiling of Ectosomes Derived from Paired Urothelial Bladder Cancer and Normal Cells Reveals the Presence of Biologically-Relevant Molecules.
Surman M; Kędracka-Krok S; Jankowska U; Drożdż A; Stępień E; Przybyło M
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202855
[TBL] [Abstract][Full Text] [Related]
10. Investigation of urinary volatile organic compounds as novel diagnostic and surveillance biomarkers of bladder cancer.
Lett L; George M; Slater R; De Lacy Costello B; Ratcliffe N; García-Fiñana M; Lazarowicz H; Probert C
Br J Cancer; 2022 Jul; 127(2):329-336. PubMed ID: 35352020
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder.
Mian C; Lodde M; Haitel A; Vigl EE; Marberger M; Pycha A
Urology; 2000 Feb; 55(2):223-6. PubMed ID: 10688083
[TBL] [Abstract][Full Text] [Related]
12. UBC®Rapid Is Sensitive in Detecting High-Grade Bladder Urothelial Carcinoma and Carcinoma in situ in Asian Population.
Zang Z; Kesavan NR; Esuvaranathan K
Urol Int; 2023; 107(1):29-34. PubMed ID: 36273445
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
[TBL] [Abstract][Full Text] [Related]
14. [Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer].
Pu XY; Wang ZP; Chen YR; Wu YL; Wang HP; Wang XH
Ai Zheng; 2008 Sep; 27(9):970-3. PubMed ID: 18799038
[TBL] [Abstract][Full Text] [Related]
15. Proteomics identification of PGAM1 as a potential therapeutic target for urothelial bladder cancer.
Peng XC; Gong FM; Chen Y; Qiu M; Cheng K; Tang J; Ge J; Chen N; Zeng H; Liu JY
J Proteomics; 2016 Jan; 132():85-92. PubMed ID: 26655504
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
[TBL] [Abstract][Full Text] [Related]
17. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
[TBL] [Abstract][Full Text] [Related]
18. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
19. IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial carcinoma of the urinary bladder (UBC).
Richter P; Junker K; Franz M; Berndt A; Geyer C; Gajda M; Kosmehl H; Berndt A; Wunderlich H
J Cancer Res Clin Oncol; 2008 Oct; 134(10):1059-65. PubMed ID: 18386055
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinicopathological features in metastatic upper tract urothelial carcinoma and urothelial bladder cancer.
Xie J; Zhang XB; Wen J; Zhang YS; Li HZ
Int Urol Nephrol; 2016 Apr; 48(4):481-7. PubMed ID: 26797856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
